119-HR-5160 DC Insider Procedural Viability Check

Institutional setup (119th Congress)

• White House: President Donald J. Trump. [2]U.S. Senate (Inaugural) — Congressional Record (Inaugural) – 2025 proceedings n…
• Senate: Republican majority; Majority Leader John Thune. HELP Committee chaired by Sen. Bill Cassidy (R-LA). [3]Office of Sen. John Thune — Sen. John Thune – First remarks as Senate Majority…
• House: Republican majority; Speaker Mike Johnson was re-elected on January 3, 2025. [4]Office of the Clerk, U.S. House of Representatives — Clerk of the House – Roll…

Bill snapshot

• Measure: H.R. 5160 — Stem Cell Therapeutic and Research Reauthorization Act of 2025. Reauthorizes the C.W. Bill Young Cell Transplantation Program and extends the National Cord Blood Inventory; updates authorizations to $33.009M annually for FY2027–FY2031. [5]Library of Congress — Congress.gov – H.R. 5160 bill text (authorization levels…
• House progress: Reported from Energy & Commerce by a 46–0 roll call vote on May 21, 2026 (amended via AINS). [1]U.S. House Committee Repository — E&C Vote Summary PDF – H.R. 5160 Final Passag…
• Senate: Companion S.4109 (Reed, Scott, Smith, Lankford) introduced March 17, 2026; referred to HELP. [6]U.S. Government Publishing Office — GovInfo – S.4109 (IS), Stem Cell Therapeuti…
• Current authorization sunsets at the end of FY2026 (September 30, 2026). [7]NIH — NIH Almanac (HRSA) – TRANSPLANT Act of 2021 reauthorized program through…

Procedural viability check (factor-by-factor)

Bottom line: this is a classic bipartisan health reauthorization with prior-cycle precedent for voice/UC passage. The question isn’t “if,” it’s “where does it hitch a ride” and “how early do they clear floor time.”

1. Chamber of Origin: House. Strong bipartisan sponsorship (Smith, Matsui, Bilirakis, Pingree, Tenney, Mfume) and unanimous committee vote signal a smooth House path, likely under suspension. Precedent: the 2021 reauth (TRANSPLANT Act) moved by voice in the Senate and 415–2 in the House. ↑ [8]network.nmdp.org
2. Vehicle Type: Stand-alone authorizing bill, ideal rider material. E&C packaged 16 health bills on May 21, 2026—clear evidence leadership is building a health extenders train for later in the year. ↑ [9]U.S. House Committee Repository — House Committee Repository – E&C Full Committ…
3. Senate Threshold: Not reconciliation-eligible; nominal 60-vote world. But the Senate companion is bipartisan and historically this program cleared by UC/voice. HELP is chaired by Cassidy (R), which reduces friction. ↑ [6]U.S. Government Publishing Office — GovInfo – S.4109 (IS), Stem Cell Therapeuti…
4. Committee Path: Aligned and productive. House E&C just reported the bill 46–0; Senate HELP has a bipartisan file in hand (S.4109). ↑ [1]U.S. House Committee Repository — E&C Vote Summary PDF – H.R. 5160 Final Passag…
5. Must-Pass Potential: Natural ride on a September L-HHS minibus/CR or a year-end health extenders package; could also move by UC as a clean two-sentence reauth. ↑ [9]U.S. House Committee Repository — House Committee Repository – E&C Full Committ…
6. Budget Scorekeeping: Tiny delta—authorization lifts from $31.009M to $33.009M annually; appropriators have been carrying ~$33.009M in recent bills. No CBO score posted yet; discretionary, with minimal PAYGO exposure. ↑/neutral. [5]Library of Congress — Congress.gov – H.R. 5160 bill text (authorization levels…
7. Calendar Math: Hard deadline is September 30, 2026. With E&C action in May and a live Senate companion since March, there’s ample runway to slot this on the pre-recess calendar or into a fall vehicle. ↑ [1]U.S. House Committee Repository — E&C Vote Summary PDF – H.R. 5160 Final Passag…

Composite score and takeaways

• Expect House floor via suspension as early as June/July; if not, park it for a fall vehicle.
• Senate can hotline/UC the House-passed text once appropriations/CR timing clarifies.
• Keep the bill scrubbed of policy riders; treat it as a clean extender to preserve unanimous consent dynamics.

Receipts (key documents)

• House E&C markup docket and vote sheet (46–0 on final passage). [9]U.S. House Committee Repository — House Committee Repository – E&C Full Committ…
• Senate companion S.4109 details and bipartisan sponsors. [6]U.S. Government Publishing Office — GovInfo – S.4109 (IS), Stem Cell Therapeuti…
• Bill text showing $33.009M authorization and FY27–31 window. [5]Library of Congress — Congress.gov – H.R. 5160 bill text (authorization levels…
• Program authorization sunset at end of FY2026; advocacy urging action before 9/30/2026. [7]NIH — NIH Almanac (HRSA) – TRANSPLANT Act of 2021 reauthorized program through…
• Institutional control: Thune as Senate Majority Leader; Cassidy chairs HELP; Speaker Johnson reelected. [3]Office of Sen. John Thune — Sen. John Thune – First remarks as Senate Majority…
• Precedent: 2021 reauthorization cleared Senate by voice vote and House 415–2. [10]Library of Congress — Congress.gov – TRANSPLANT Act of 2021: actions (Senate pa…
• Appropriations context carrying ~$33.009M for the program. [11]U.S. House of Representatives — House Appropriations Committee print (FY2025) n…